TY - JOUR
T1 - K-carrageenan stimulates pre-osteoblast proliferation and osteogenic differentiation
T2 - A potential factor for the promotion of bone regeneration?
AU - Cao, Wei
AU - Jin, Jianfeng
AU - Wu, Gang
AU - Bravenboer, Nathalie
AU - Helder, Marco N.
AU - Pathak, Janak L.
AU - Zandieh-Doulabi, Behrouz
AU - Hogervorst, Jolanda M.A.
AU - Matsukawa, Shingo
AU - Geonzon, Lester C.
AU - Bacabac, Rommel G.
AU - Schulten, Engelbert A.J.M.
AU - Klein-Nulend, Jenneke
N1 - Funding Information:
Funding: This work was granted by the China Scholarship Council (CSC, no. 201808440487 (W. Cao) and no. 201608530156 (J. Jin)). This work was also granted by Health-Holland (project no. LSHM19016, “BB”). L.C. Geonzon received financial support of JSPS KAKENHI grant no.20F20388. R.G. Bacabac was funded by DOST-PCIEERD project no. 09438, and received logistic support from the USC Research Office and Department of Physics.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10/2
Y1 - 2021/10/2
N2 - Current cell-based bone tissue regeneration strategies cannot cover large bone defects. K-carrageenan is a highly hydrophilic and biocompatible seaweed-derived sulfated polysaccharide, that has been proposed as a promising candidate for tissue engineering applications. Whether κ-carrageenan can be used to enhance bone regeneration is still unclear. In this study, we aimed to investigate whether κ-carrageenan has osteogenic potential by testing its effect on pre-osteoblast proliferation and osteogenic differentiation in vitro. Treatment with κ-carrageenan (0.5 and 2 mg/mL) increased both MC3T3-E1 pre-osteoblast adhesion and spreading at 1 h. K-carrageenan (0.125–2 mg/mL) dose-dependently increased pre-osteoblast proliferation and metabolic activity, with a maximum effect at 2 mg/mL at day three. K-carrageenan (0.5 and 2 mg/mL) increased osteogenic differentiation, as shown by enhanced alkaline phosphatase activity (1.8-fold increase at 2 mg/mL) at day four, and matrix mineralization (6.2-fold increase at 2 mg/mL) at day 21. K-carrageenan enhanced osteogenic gene expression (Opn, Dmp1, and Mepe) at day 14 and 21. In conclusion, κ-carrageenan promoted MC3T3-E1 pre-osteoblast adhesion and spreading, metabolic activity, proliferation, and osteogenic differentiation, suggesting that κ-carrageenan is a potential osteogenic inductive factor for clinical application to enhance bone regeneration.
AB - Current cell-based bone tissue regeneration strategies cannot cover large bone defects. K-carrageenan is a highly hydrophilic and biocompatible seaweed-derived sulfated polysaccharide, that has been proposed as a promising candidate for tissue engineering applications. Whether κ-carrageenan can be used to enhance bone regeneration is still unclear. In this study, we aimed to investigate whether κ-carrageenan has osteogenic potential by testing its effect on pre-osteoblast proliferation and osteogenic differentiation in vitro. Treatment with κ-carrageenan (0.5 and 2 mg/mL) increased both MC3T3-E1 pre-osteoblast adhesion and spreading at 1 h. K-carrageenan (0.125–2 mg/mL) dose-dependently increased pre-osteoblast proliferation and metabolic activity, with a maximum effect at 2 mg/mL at day three. K-carrageenan (0.5 and 2 mg/mL) increased osteogenic differentiation, as shown by enhanced alkaline phosphatase activity (1.8-fold increase at 2 mg/mL) at day four, and matrix mineralization (6.2-fold increase at 2 mg/mL) at day 21. K-carrageenan enhanced osteogenic gene expression (Opn, Dmp1, and Mepe) at day 14 and 21. In conclusion, κ-carrageenan promoted MC3T3-E1 pre-osteoblast adhesion and spreading, metabolic activity, proliferation, and osteogenic differentiation, suggesting that κ-carrageenan is a potential osteogenic inductive factor for clinical application to enhance bone regeneration.
KW - Bone defect
KW - Bone regeneration
KW - Cell proliferation
KW - Cell-based bone tissue engineering
KW - MC3T3-E1 pre-osteoblast
KW - Osteogenic differentiation
KW - κ-carrageenan
UR - http://www.scopus.com/inward/record.url?scp=85117182117&partnerID=8YFLogxK
U2 - 10.3390/molecules26206131
DO - 10.3390/molecules26206131
M3 - Article
C2 - 34684714
AN - SCOPUS:85117182117
SN - 1420-3049
VL - 26
JO - Molecules
JF - Molecules
IS - 20
M1 - 6131
ER -